Global Female Contraceptive Market 2016-2020

女性用避妊用具・避妊薬の世界市場2016-2020

◆タイトル:Global Female Contraceptive Market 2016-2020
◆商品コード:IRTNTR10676
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2016年10月27日
◆ページ数:78
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:消費財
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥265,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥318,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥424,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、女性用避妊用具・避妊薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、女性用避妊用具・避妊薬の世界市場規模及び予測、製品別分析、地域別分析/市場規模、主要国別分析、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

・エグゼクティブサマリー
・女性用避妊用具・避妊薬の世界市場:市場概観
・女性用避妊用具・避妊薬の世界市場:業界の構造分析
・女性用避妊用具・避妊薬の世界市場:市場規模及び予測
・女性用避妊用具・避妊薬の世界市場:製品別分析
・女性用避妊用具・避妊薬の世界市場:地域別分析
・女性用避妊用具・避妊薬の世界市場:アジア市場規模
・女性用避妊用具・避妊薬の世界市場:アメリカ市場規模
・女性用避妊用具・避妊薬の世界市場:アメリカ市場規模
・女性用避妊用具・避妊薬の世界市場:ヨーロッパ市場規模
・女性用避妊用具・避妊薬の世界市場:主要国別分析
・女性用避妊用具・避妊薬の世界市場:成長要因
・女性用避妊用具・避妊薬の世界市場:課題
・女性用避妊用具・避妊薬の世界市場:市場動向
・女性用避妊用具・避妊薬の世界市場:競争状況
・女性用避妊用具・避妊薬の世界市場:主要企業(ベンダー)分析
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

About Female Contraceptives
Adolescent fertility regulation and pregnancy prevention are important healthcare issues today. Although it is difficult to gauge the full extent of the unmet need for contraception, there is a great need for reproductive and sexual health education owing to the rise in STDs. Research suggests that behavior in adolescence results in a pattern for the rest of an individual’s life. The absence of sexual and reproductive healthcare programs for adolescents can result in unwanted pregnancies and unsafe abortions.

Technavio’s analysts forecast the global female contraceptive market to grow at a CAGR of 3.48% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global female contraceptives market for 2016-2020. To calculate the market size, the report considers the revenue generated from the overall retail sales of female contraceptive products globally.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Female Contraceptives 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Allergan
• Merck Millipore
• Pfizer
• Teva Pharmaceuticals

[Other prominent vendors]
• Afaxys
• Agile Therapeutics
• Ansell
• Bayer Pharma
• Caya
• Ferring Pharmaceuticals
• Female Health
• Fuji Latex
• HLL Lifecare
• Janssen Pharmaceuticals
• Lipocine
• Lupin Pharmaceuticals
• Mayer Laboratories
• Okamoto Industries
• Reckitt Benckiser
• Syzygy Healthcare
• V-Care Pharma

[Market driver]
• Growing importance of family planning
• For a full, detailed list, view our report

[Market challenge]
• High cost and inaccessibility of health services
• For a full, detailed list, view our report

[Market trend]
• Growing cases of sexually transmitted diseases (STDs)
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Market landscape
• Market overview
• Five forces analysis

PART 06: Geographical segmentation
• Global female contraceptive market by geography
• Female contraceptive market in Americas
• Female contraceptive market in EMEA
• Female contraceptive market in APAC

PART 07: Product segmentation
• Global female contraceptive market by product segmentation
• Global female contraceptive market by devices
• Global IUD market
• Global sterilization market
• Global subdermal contraceptive implant market
• Global vaginal ring market
• Global female condom market
• Global non-surgical permanent contraception market
• Global contraceptive diaphragm market
• Global contraceptive sponge market
• Global female contraceptive drug market
• Global birth control pill market
• Global emergency pill market

PART 08: Market drivers

PART 09: Impact of drivers

PART 10: Market challenges

PART 11: Impact of drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape
• Competitive scenario

PART 14: Key vendor analysis
• Allergan
• Merck Millipore
• Pfizer
• Teva Pharmaceuticals
• Other prominent vendors

PART 15: Appendix
• List of abbreviations

PART 16: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Global female contraceptive market: An overview
Exhibit 03: Advantages and disadvantages of different types of contraceptives
Exhibit 04: Effectiveness of female contraceptives
Exhibit 05: Global female contraceptive market ($ billions)
Exhibit 06: Impact factors of the global female contraceptive market
Exhibit 07: Investment opportunity in global female contraceptive market
Exhibit 08: Effectiveness of family planning methods
Exhibit 09: Top-ranked women health issues 2015
Exhibit 10: Five forces analysis
Exhibit 11: Global female contraceptive market by geography 2015-2020 (% share)
Exhibit 12: Global female contraceptive market by geography 2015-2020
Exhibit 13: Female contraceptive market in the Americas 2015-2020 ($ billions)
Exhibit 14: Percentage of women aged 15-44 using modern contraceptives in US 2015
Exhibit 15: Key leading countries
Exhibit 16: Female contraceptive market in EMEA 2015-2020 ($ billions)
Exhibit 17: Key leading countries
Exhibit 18: Female contraceptive market in APAC 2015-2020 ($ billions)
Exhibit 19: Key leading countries
Exhibit 20: Global female contraceptive market by product segmentation 2015 (% share)
Exhibit 21: Opportunity analysis for global female contraceptive market by product segmentation
Exhibit 22: Global female contraceptive device market 2015-2020 ($ billions)
Exhibit 23: Global female contraceptive device market by type 2015-2020
Exhibit 24: Global IUD market 2015-2020 ($ millions)
Exhibit 25: Global sterilization market 2015-2020 ($ millions)
Exhibit 26: Global subdermal contraceptive implant market 2015-2020 ($ millions)
Exhibit 27: Global vaginal ring market 2015-2020 ($ millions)
Exhibit 28: Global female condom market 2015-2020 ($ millions)
Exhibit 29: Global non-surgical permanent contraception market 2015-2020 ($ millions)
Exhibit 30: Global contraceptive diaphragm market 2015-2020 ($ millions)
Exhibit 31: Global contraceptive sponge market 2015-2020 ($ millions)
Exhibit 32: Global female contraceptive drug market 2015-2020 ($ billions)
Exhibit 33: Global female contraceptive market by type 2015 and 2020
Exhibit 34: Global birth control pill market 2015-2020 ($ millions)
Exhibit 35: Global emergency pill market 2015-2020 ($ millions)
Exhibit 36: Key leading countries in emergency pills
Exhibit 37: Unplanned pregnancies by region (millions)
Exhibit 38: Impact of drivers
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Non-contraceptive health benefits
Exhibit 41: Population of women using birth pills for non-contraceptive reasons
Exhibit 42: Competitive parameters in global female contraceptive market
Exhibit 43: Strategic success factor of companies
Exhibit 44: Key takeaways
Exhibit 45: Key takeaways
Exhibit 46: Pfizer: Key takeaways



【掲載企業】

Allergan, Merck Millipore, Pfizer, Teva, Afaxys, Agile Therapeutics, Ansell, Bayer Pharma, Caya, Ferring Pharmaceuticals, Female Health, Fuji Latex, HLL Lifecare, Janssen Pharmaceuticals, Lipocine, Lupin Pharmaceuticals, Mayer Laboratories, Okamoto Industries, Reckitt Benckiser, Syzygy Healthcare, V-Care Pharma

【資料のキーワード】

女性用避妊用具、女性用避妊薬、子宮内避妊用具、経口避妊薬、妊娠、女性用コンドーム

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[女性用避妊用具・避妊薬の世界市場2016-2020]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆